Looks like it could have some legs here for a swing bounce.
FATE. Have Faith in this stock. Could snap back to previous channel fast. Big institional value and insider value.
No earnings report as of late so I tried to find out what the deal is. Looks like an analyst' downgrade on Friday and some other bad news. Short is over 24%. Makes you scratch your head and think WOW! No recommendation/Dust needs to settle and I guess even dirt can get cheaper )o:
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and...
FATE is an interesting company, just developing. There are about 480 thousand in cash, an annual loss of 173 thousand, Has 8 studies in 1 phase. Probably, it will “accumulate” one more year before significant phase studies (3), which corresponds to the negative scenario. And 2 in partnership with Janssen and Ono Pharma. Curious FT596 with rituximab and FT538 with...
Please review any tips or thoughts is helpful. 1 to 4 risk to reward Stop loss 69 Short term price target $78 Risking $2 for $8 a share.
3 to 4 weeks on the 30 min chart. Staying patient, hoping bullish wedge forms before the dead cat bounce swing. Some Bollinger band squeezes energy behind it. Let's see! NASDAQ:FATE
Looking to place some Leaps on FATE as hedge funds pile up on this biotech stock
Go long if prices take out today's high. Stop underneath the bear trap.
MRNA leading fate higher, MACD and RSI curling up, A+ setup, im very bullish biotech rn
Bullish Pennant Pros: Descending volume during formation PPS above 50MA and 200MA RS above 0, and ascending ATR Ascending R/R ratio above 5 200MA ascending 250RSI above 50 Price Target: PT = 145.41$
Hot sector, high tight flag, 10MA, VPA, Inside day NASDAQ:FATE
shorting this stock - FATE - for my own records.